Trade vTv Therapeutics Inc. - VTVT CFD

Add to favourite

23.86

2.17%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.73

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

vTv Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	24.39
Open*	23.7
1-Year Change*	3146.58%
Day's Range*	23.2 - 23.86
52 wk Range	0.35-1.05
Average Volume (10 days)	134.80K
Average Volume (3 months)	2.00M
Market Cap	36.60M
P/E Ratio	-100.00K
Shares Outstanding	104.58M
Revenue	9,000.00
EPS	-0.26
Dividend (Yield %)	N/A
Beta	-0.06
Next Earnings Date	Mar 4, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 19, 2024	23.86	0.16	0.68%	23.70	23.86	23.20
Apr 18, 2024	24.39	1.43	6.23%	22.96	24.39	22.96
Apr 17, 2024	23.82	-0.97	-3.91%	24.79	24.79	23.37
Apr 16, 2024	24.07	0.04	0.17%	24.03	24.31	24.03
Apr 15, 2024	23.92	1.00	4.36%	22.92	24.55	22.92
Apr 12, 2024	25.00	0.59	2.42%	24.41	25.00	24.41
Apr 11, 2024	24.56	0.05	0.20%	24.51	25.21	24.27
Apr 10, 2024	24.21	-0.22	-0.90%	24.43	24.43	23.42
Apr 9, 2024	24.15	0.20	0.84%	23.95	24.40	23.95
Apr 8, 2024	24.71	-0.38	-1.51%	25.09	25.16	23.91
Apr 5, 2024	24.83	0.82	3.42%	24.01	25.17	24.01
Apr 4, 2024	24.89	0.47	1.92%	24.42	25.12	24.37
Apr 3, 2024	24.37	0.30	1.25%	24.07	24.81	23.31
Apr 2, 2024	24.41	0.00	0.00%	24.41	24.67	24.41
Apr 1, 2024	23.67	0.36	1.54%	23.31	25.17	23.31
Mar 28, 2024	23.13	-0.62	-2.61%	23.75	24.41	22.13
Mar 27, 2024	22.67	0.13	0.58%	22.54	24.71	21.93
Mar 26, 2024	21.93	1.93	9.65%	20.00	22.42	20.00
Mar 25, 2024	20.48	-2.39	-10.45%	22.87	23.25	19.04
Mar 22, 2024	21.67	-7.18	-24.89%	28.85	28.90	20.94

vTv Therapeutics Inc. Events

Time (UTC)	Country	Event
Thursday, May 9, 2024
Time (UTC) 10:59	Country US	Event Q1 2024 vTv Therapeutics Inc Earnings Release Q1 2024 vTv Therapeutics Inc Earnings Release Forecast - Previous -
Wednesday, June 5, 2024
Time (UTC) 13:00	Country US	Event vTv Therapeutics Inc Annual Shareholders Meeting vTv Therapeutics Inc Annual Shareholders Meeting Forecast - Previous -
Friday, August 9, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 vTv Therapeutics Inc Earnings Release Q2 2024 vTv Therapeutics Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	2.018	4.005	6.414	2.764	12.434
Revenue	2.018	4.005	6.414	2.764	12.434
Total Operating Expense	24.558	25.667	18.266	23.656	32.258
Selling/General/Admin. Expenses, Total	12.201	11.443	7.251	8.537	9.223
Research & Development	12.357	12.624	11.015	15.119	23.035
Operating Income	-22.54	-21.662	-11.852	-20.892	-19.824
Interest Income (Expense), Net Non-Operating	0.337	-0.011	-0.68	-1.774	-3.229
Other, Net	-2.67	4.057	-0.27	0.828	-0.592
Net Income Before Taxes	-24.873	-17.616	-12.802	-21.838	-23.645
Net Income After Taxes	-25.073	-17.731	-12.802	-21.938	-23.845
Minority Interest	5.909	4.744	4.303	8.894	15.934
Net Income Before Extra. Items	-19.164	-12.987	-8.499	-13.044	-7.911
Net Income	-19.164	-12.987	-8.499	-13.044	-7.911
Income Available to Common Excl. Extra. Items	-19.164	-12.987	-8.499	-17.913	-8.65
Income Available to Common Incl. Extra. Items	-19.164	-12.987	-8.499	-17.913	-8.65
Diluted Net Income	-19.164	-12.987	-8.499	-17.913	-8.65
Diluted Weighted Average Shares	74.8762	60.7326	47.1379	30.292	12.4492
Diluted EPS Excluding Extraordinary Items	-0.25594	-0.21384	-0.1803	-0.59134	-0.69482
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS	-0.25594	-0.19671	-0.1803	-0.59134	-0.69482
Total Extraordinary Items
Total Adjustments to Net Income			0	-4.869	-0.739
Unusual Expense (Income)		1.6

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0	0	0.009	0	0.009
Revenue	0	0	0.009	0	0.009
Total Operating Expense	8	7.127	6.352	5.689	4.036
Selling/General/Admin. Expenses, Total	3.309	3.485	2.388	2.634	1.831
Research & Development	4.691	3.942	3.964	3.055	2.205
Operating Income	-8	-7.127	-6.343	-5.689	-4.027
Interest Income (Expense), Net Non-Operating	0.151	0.1	0.146	0.142	0.05
Other, Net	0.638	1.253	0.107	0.079	-0.114
Net Income Before Taxes	-7.211	-5.774	-6.09	-5.468	-4.091
Net Income After Taxes	-7.211	-5.774	-6.09	-5.468	-4.091
Minority Interest	1.592	1.275	1.345	1.207	0.94
Net Income Before Extra. Items	-5.619	-4.499	-4.745	-4.261	-3.151
Net Income	-5.619	-4.499	-4.745	-4.261	-3.151
Income Available to Common Excl. Extra. Items	-5.619	-4.499	-4.745	-4.261	-3.151
Income Available to Common Incl. Extra. Items	-5.619	-4.499	-4.745	-4.261	-3.151
Diluted Net Income	-5.619	-4.499	-4.745	-4.261	-3.151
Diluted Weighted Average Shares	81.4836	81.4836	81.5562	80.4901	70.3668
Diluted EPS Excluding Extraordinary Items	-0.06896	-0.05521	-0.05818	-0.05294	-0.04478
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.06896	-0.0589	-0.05818	-0.05294	-0.04478
Unusual Expense (Income)		-0.3

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	27.094	15.621	7.215	2.838	3.473
Cash and Short Term Investments	12.126	13.415	5.747	1.777	1.683
Cash & Equivalents	12.126	13.415	5.747	1.777	1.683
Total Receivables, Net	12.416	0.057	0.158	0.005	0
Accounts Receivable - Trade, Net	12.416	0.057	0.158	0.005	0
Prepaid Expenses	2.537	1.914	0.939	0.806	0.666
Total Assets	33.238	25.474	14.789	9.266	8.559
Property/Plant/Equipment, Total - Net	0.556	0.68	0.849	1.004	0.07
Property/Plant/Equipment, Total - Gross	0.953	0.985	1.065	1.152	8.501
Accumulated Depreciation, Total	-0.397	-0.305	-0.216	-0.148	-8.431
Other Long Term Assets, Total			0	2.944	2.536
Total Current Liabilities	7.708	8.498	6.39	13.381	18.837
Accounts Payable	2.461	1.876	1.925	2.232	2.899
Payable/Accrued
Accrued Expenses	5.006	6.331	4.35	4.946	4.803
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	0.017	0.035	0.031	0.031	1.752
Total Liabilities	43.978	35.214	94.891	58.289	91.412
Total Long Term Debt	0	0	0	0	6.33
Long Term Debt				0	6.33
Minority Interest	16.579	24.962	83.895	40.183	62.482
Other Liabilities, Total	19.691	1.754	4.606	4.725	3.763
Total Equity	-10.74	-9.74	-80.102	-49.023	-82.853
Common Stock	1.047	0.901	0.773	0.641	0.435
Additional Paid-In Capital	253.737	238.193	209.161	183.858	150.595
Retained Earnings (Accumulated Deficit)	-265.524	-248.834	-290.036	-233.522	-233.883
Total Liabilities & Shareholders’ Equity	33.238	25.474	14.789	9.266	8.559
Total Common Shares Outstanding	104.577	90.0366	77.1449	64.0127	43.4413
Other Current Assets, Total	0.015	0.235	0.371	0.25	1.124
Long Term Investments	5.588	9.173	6.725	2.48	2.48
Current Port. of LT Debt/Capital Leases	0.224	0.256	0.084	6.172	9.383

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total Current Assets	13.938	20.627	27.094	28.783	30.609
Cash and Short Term Investments	12.599	18.766	12.126	15.339	17.863
Cash & Equivalents	12.599	18.766	12.126	15.339	17.863
Total Receivables, Net	0	0	12.416	12.148	12.018
Accounts Receivable - Trade, Net	0	0	12.416	12.148	12.018
Prepaid Expenses	1.324	1.846	2.537	1.281	0.643
Other Current Assets, Total	0.015	0.015	0.015	0.015	0.085
Total Assets	22.426	28.828	33.238	35.516	36.989
Property/Plant/Equipment, Total - Net	0.461	0.509	0.556	0.558	0.608
Long Term Investments	8.027	7.692	5.588	6.175	5.772
Total Current Liabilities	9.286	8.532	7.708	7.467	9.825
Payable/Accrued	9.108	8.358	7.313	6.676	9.6
Accrued Expenses	0.161	0.157	0.154	0.208	0.199
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	0	0	0.224	0.557	0
Other Current Liabilities, Total	0.017	0.017	0.017	0.026	0.026
Total Liabilities	47.709	48.02	43.978	52.085	45.515
Total Long Term Debt	0	0	0	0	0
Minority Interest	18.879	19.6	16.579	24.207	15.916
Other Liabilities, Total	19.544	19.888	19.691	20.411	19.774
Total Equity	-25.283	-19.192	-10.74	-16.569	-8.526
Common Stock	1.047	1.047	1.047	1.047	1.005
Additional Paid-In Capital	254.479	254.08	253.737	253.446	243.772
Retained Earnings (Accumulated Deficit)	-280.809	-274.319	-265.524	-267.062	-253.303
Total Liabilities & Shareholders’ Equity	22.426	28.828	33.238	35.516	36.989
Total Common Shares Outstanding	104.577	104.577	104.577	104.577	100.423
Other Equity, Total				-4

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-25.073	-17.731	-12.802	-21.938	-23.845
Cash From Operating Activities	-16.022	-19.308	-18	-23.018	-26.856
Cash From Operating Activities	0.092	0.089	0.094	0.039	0.218
Non-Cash Items	3.911	-1.701	-2.586	0.935	4.316
Cash Interest Paid	0.015	0.011	0.623	1.295	2.276
Changes in Working Capital	5.048	0.035	-2.706	-2.054	-7.545
Cash From Investing Activities	-0.021	0	0	0.242	0.007
Capital Expenditures	-0.021	0	0	-0.07	-0.005
Other Investing Cash Flow Items, Total		0	0	0.312	0.012
Cash From Financing Activities	14.754	26.976	19.47	22.87	16.612
Financing Cash Flow Items					0
Issuance (Retirement) of Stock, Net	14.786	26.804	24.426	32.943	21.5
Issuance (Retirement) of Debt, Net	-0.032	0.172	-4.956	-10.073	-4.888
Net Change in Cash	-1.289	7.668	1.47	0.094	-10.237
Cash Taxes Paid	0.2	0.115	0	0.1	1

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-5.774	-25.073	-18.983	-13.515	-9.424
Cash From Operating Activities	-5.166	-16.022	-9.142	-0.315	-1.021
Cash From Operating Activities	0.022	0.092	0.069	0.045	0.023
Non-Cash Items	-1.21	3.911	3.758	3.499	3.218
Changes in Working Capital	1.796	5.048	6.014	9.656	5.162
Cash From Financing Activities	11.806	14.754	11.087	4.784	-0.256
Issuance (Retirement) of Stock, Net	12.03	14.786	10.786	5.04	0
Issuance (Retirement) of Debt, Net	-0.224	-0.032	0.301	-0.256	-0.256
Net Change in Cash	6.64	-1.289	1.924	4.448	-1.277
Cash From Investing Activities		-0.021	-0.021	-0.021
Capital Expenditures		-0.021	-0.021	-0.021
Other Investing Cash Flow Items, Total

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

vTv Therapeutics Inc. Company profile

About vTv Therapeutics Inc

vTv Therapeutics Inc. is a clinical-stage pharmaceutical company that is engaged in the discovery and development of orally administered small molecule drug candidates. It is developing a program for the treatment of type I diabetes TTP399 and for psoriasis HPP737. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. The Company is also conducting a multiple ascending dose Phase I study of HPP737, an orally administered phosphodiesterase type IV inhibitor, to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of HPP737 in healthy volunteers as part of its psoriasis program. Its TTP273 is an oral, small molecule, glucagon-like peptide I (GLP-1) receptor agonist being evaluated for the treatment of type II diabetes mellitus.

Financial summary

BRIEF: For the nine months ended 30 September 2021, vTv Therapeutics Inc revenues increased from $15K to $4M. Net loss decreased 38% to $5.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other (expense) income increase from $0K to $1.8M (income), Research and Development - Balancing decrease of 10% to $7.4M (expense).

Industry:

Bio Therapeutic Drugs

3980 Premier Dr
Suite 310
27265

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024